Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
City of Hope Medical Center
Bristol-Myers Squibb
SWOG Cancer Research Network
Pfizer
Pfizer
Genentech, Inc.
Yonsei University
Tang-Du Hospital
University of Chicago
PrECOG, LLC.
Hunan Province Tumor Hospital
Institut Paoli-Calmettes
Fudan University
Guangdong Provincial People's Hospital
Shanghai JMT-Bio Inc.
Guangzhou University of Traditional Chinese Medicine
Duke University
Peking Union Medical College Hospital
Sun Yat-sen University
UNICANCER
Abramson Cancer Center at Penn Medicine
Chongqing University Cancer Hospital
Shanghai Pulmonary Hospital, Shanghai, China
Fudan University
University of Rochester
Sichuan University
Fundación GECP
Varian, a Siemens Healthineers Company
Tianjin Medical University Cancer Institute and Hospital
University of Washington
Anhui Provincial Cancer Hospital
Daiichi Sankyo
Sichuan University
Abramson Cancer Center at Penn Medicine
Alliance for Clinical Trials in Oncology
Shenyang Sunshine Pharmaceutical Co., LTD.
TheraOp
Università Vita-Salute San Raffaele
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
University Medical Centre Maribor
Sichuan University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Peking Union Medical College
Fudan University
Krystal Biotech, Inc.
Shanghai Henlius Biotech
Bristol-Myers Squibb
Fudan University
First Affiliated Hospital of Wenzhou Medical University
Gustave Roussy, Cancer Campus, Grand Paris